Albumin Paclitaxel Composition Assessment Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the suitability of albumin-based paclitaxel pharmaceutical compositions for medical use lack comprehensive and precise criteria, particularly in determining the optimal composition of albumin polymers, monomers, and their ratios, which affects drug delivery and solubility.
Innovation Solution
A method is developed to assess the suitability of pharmaceutical compositions comprising paclitaxel-coated nanoparticles with albumin by determining specific physicochemical characteristics such as the percentage of albumin polymers, monomers, and their ratios, as well as the weight percentage of albumin and paclitaxel, morphology, solubility, and crystallinity, to ensure effective drug delivery and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If comprehensive assessment criteria including albumin polymer percentage, monomer percentage, and their ratios are established, then measurement precision and manufacturing precision are improved, but device complexity and ease of operation worsen
Solution Approach 1:
The assessment method is segmented into distinct measurement components: determining albumin polymer percentage, determining albumin monomer percentage, and calculating their ratios. Each component can be independently measured and evaluated, allowing for systematic assessment without requiring a single complex measurement system.
Solution Approach 2:
The method utilizes changes in physical and chemical parameters of the pharmaceutical composition, specifically focusing on the oligomeric status (polymer vs monomer percentages) of albumin. By monitoring these parameter changes, the assessment achieves high precision through measuring fundamental compositional properties rather than complex functional behaviors.
2Manufacturing precision
If multiple physicochemical characteristics including morphology, solubility, and crystallinity are determined, then manufacturing precision is improved, but loss of time increases
Solution Approach 1:
The method performs preliminary assessments of key physicochemical characteristics during the manufacturing process rather than as separate post-manufacturing tests. By determining albumin polymer/monomer percentages and other characteristics as part of the composition control process, time is saved by eliminating sequential testing steps.
Solution Approach 2:
The assessment method serves multiple functions simultaneously: it evaluates composition accuracy, predicts in vivo performance, and ensures product stability all through a single integrated analysis of albumin oligomeric status and related parameters. This multi-functionality reduces the need for separate specialized tests.
Data Source
AI summary
The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising paclitaxel coated with albumin and a non-nanoparticle portion comprising albumin and paclitaxel.